The University of Queensland, UQ Centre for Clinical Research, Herston, Brisbane, Queensland, Australia.
Microb Drug Resist. 2013 Apr;19(2):100-3. doi: 10.1089/mdr.2012.0063. Epub 2013 Jan 18.
The New Delhi metallo-β-lactamase gene (bla(NDM-1)) has emerged as a worldwide concern among isolates of Enterobacteriaceae. Its epidemiology is been strongly associated with travel and healthcare on the Indian Subcontinent. We report two cases of urinary tract infection with Enterobacteriaceae harboring a bla(NDM-1). Both cases presented as infection in community-dwelling individuals in Australia and were associated with travel to the Indian Subcontinent. One isolate of Escherichia coli harbored the previously undescribed enzyme variant bla(NDM-3), differing from bla(NDM-1) by a single nonsynonymous SNP conferring a putative peptide sequence change at the 95th position (ASP→ASN). The second was an Enterobacter cloacae harboring bla(NDM-1). Further genetic characterization included identification of additional β-lactamase and aminoglycoside resistance genes. Legacy antimicrobials were used for treatment. Oral therapy with nitrofurantoin was successful in one case, while combination of colistin and rifampicin was required in the second patient. Such infection, due to extensively drug-resistant pathogens, poses significant challenges in balancing the efficacy and toxicity of potential antimicrobial therapies.
新德里金属β-内酰胺酶基因(bla(NDM-1))已成为肠杆菌科分离株中引起全球关注的问题。其流行病学与印度次大陆的旅行和医疗保健密切相关。我们报告了两例携带 bla(NDM-1)的尿路感染的肠杆菌科病例。两例均为澳大利亚社区居住者的感染,与前往印度次大陆旅行有关。一株大肠杆菌携带了先前未描述的酶变体 bla(NDM-3),与 bla(NDM-1)相比,该变体仅发生了一个非同义 SNP,导致第 95 位的假定肽序列发生变化(ASP→ASN)。第二株是一株携带 bla(NDM-1)的阴沟肠杆菌。进一步的遗传特征包括鉴定其他β-内酰胺酶和氨基糖苷类耐药基因。传统的抗菌药物用于治疗。一例患者成功接受了呋喃妥因口服治疗,而第二例患者需要联合使用多粘菌素和利福平。由于存在广泛耐药的病原体,此类感染在平衡潜在抗菌治疗的疗效和毒性方面带来了重大挑战。